GM1 gangliosidosis

Views & Analysis

Rare disease families need to stand up and be counted if they want things to change said mum and advocate Christine Waggoner.

News

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.